InMed Pharmaceuticals IncNASDAQ:INMNASDAQ FSI:D. Deficient (Issuer failed to meet continued listing requirements)
- LAST PRICE0.2237
- TODAY'S CHANGE (%)-0.0194 (-7.9630%)
- Bid / Lots0.2195/ 5
- Ask / Lots0.2282/ 51
- Open / Previous Close0.2347 / 0.2430
- Day Range
- 52 Week Range
- Volume562,640
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | INM |
|---|---|---|
| 09:32 ET | 5958 | 0.2347 |
| 09:33 ET | 8521 | 0.24 |
| 09:35 ET | 11000 | 0.239 |
| 09:37 ET | 11695 | 0.2301 |
| 09:42 ET | 661 | 0.2304 |
| 09:46 ET | 600 | 0.2385 |
| 09:48 ET | 200 | 0.2341 |
| 09:50 ET | 4260 | 0.241139 |
| 09:51 ET | 1000 | 0.2394 |
| 09:53 ET | 3600 | 0.2354 |
| 09:55 ET | 12000 | 0.235 |
| 09:57 ET | 200 | 0.2337 |
| 10:00 ET | 600 | 0.24 |
| 10:06 ET | 1000 | 0.2399 |
| 10:08 ET | 112 | 0.2327 |
| 10:09 ET | 200 | 0.2384 |
| 10:11 ET | 4500 | 0.2314 |
| 10:13 ET | 1120 | 0.238 |
| 10:15 ET | 1500 | 0.2384 |
| 10:18 ET | 770 | 0.2384 |
| 10:24 ET | 100 | 0.2314 |
| 10:27 ET | 7351 | 0.2314 |
| 10:33 ET | 1700 | 0.238 |
| 10:38 ET | 4000 | 0.2377 |
| 10:42 ET | 7754 | 0.23 |
| 10:47 ET | 3000 | 0.23 |
| 10:58 ET | 20200 | 0.2297 |
| 11:03 ET | 2500 | 0.23 |
| 11:05 ET | 19218 | 0.2321 |
| 11:07 ET | 7748 | 0.2323 |
| 11:09 ET | 9239 | 0.232 |
| 11:16 ET | 5100 | 0.23 |
| 11:21 ET | 2153 | 0.2374 |
| 11:34 ET | 1289 | 0.2302 |
| 11:36 ET | 7188 | 0.2302 |
| 11:39 ET | 200 | 0.2301 |
| 11:48 ET | 10168 | 0.2306 |
| 11:50 ET | 10200 | 0.2312 |
| 12:03 ET | 5000 | 0.2313 |
| 12:06 ET | 700 | 0.2358 |
| 12:12 ET | 6538 | 0.235 |
| 12:15 ET | 500 | 0.235 |
| 12:17 ET | 10320 | 0.2359 |
| 12:19 ET | 140 | 0.2358 |
| 12:21 ET | 3200 | 0.2358 |
| 12:24 ET | 300 | 0.230101 |
| 12:28 ET | 700 | 0.2359 |
| 12:32 ET | 22500 | 0.2376 |
| 12:55 ET | 20000 | 0.232 |
| 12:57 ET | 201 | 0.2312 |
| 01:00 ET | 772 | 0.2313 |
| 01:02 ET | 3825 | 0.2313 |
| 01:08 ET | 380 | 0.236 |
| 01:20 ET | 10200 | 0.2312 |
| 01:22 ET | 30000 | 0.232 |
| 01:24 ET | 100 | 0.2313 |
| 01:31 ET | 240 | 0.232 |
| 01:33 ET | 100 | 0.2306 |
| 01:40 ET | 40578 | 0.2317 |
| 01:54 ET | 920 | 0.2327 |
| 02:05 ET | 145 | 0.2327 |
| 02:09 ET | 5272 | 0.22995 |
| 02:12 ET | 11836 | 0.2268 |
| 02:14 ET | 10200 | 0.2236 |
| 02:18 ET | 1200 | 0.2225 |
| 02:21 ET | 2596 | 0.2278 |
| 02:32 ET | 11733 | 0.228 |
| 02:43 ET | 300 | 0.2289 |
| 03:06 ET | 300 | 0.2249 |
| 03:08 ET | 2200 | 0.2253 |
| 03:15 ET | 100 | 0.2249 |
| 03:21 ET | 1000 | 0.224999 |
| 03:26 ET | 1800 | 0.2216 |
| 03:32 ET | 100 | 0.222 |
| 03:33 ET | 500 | 0.2222 |
| 03:44 ET | 950 | 0.225 |
| 03:51 ET | 100 | 0.225 |
| 03:57 ET | 737 | 0.2223 |
| 04:00 ET | 294 | 0.22365 |
Today
Oct 28, 2024
Oct 24, 2024
InMed to Participate in Fierce Biotech Webinar on Neuroinflammation in Alzheimer's Disease, from 8:02AM ET on Thursday Oct 24, 2024 by Dow Jones
8:02AM ET on Thursday Oct 24, 2024 by Dow Jones
Oct 22, 2024
InMed Appoints Dr. Barry Greenberg, Johns Hopkins University School of Medicine, to its Scientific Advisory Board, from 8:02AM ET on Tuesday Oct 22, 2024 by Dow Jones
8:02AM ET on Tuesday Oct 22, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
InMed Pharmaceuticals Inc | 3.2M | -0.2x | --- |
Stemtech Corp | 3.2M | -0.5x | --- |
Plus Therapeutics Inc | 8.0M | -0.4x | --- |
Histogen Inc | 897.1K | -0.1x | --- |
Petros Pharmaceuticals Inc | 3.4M | -0.1x | --- |
Athersys Inc | 60.0 | 0.0x | --- |
Company Information
InMed Pharmaceuticals Inc. is a pharmaceutical company. It develops a pipeline of small molecule drug candidates targeting the CB1/CB2 receptors. Its InMed Pharmaceuticals segment is engaged in the research and development of small molecule pharmaceuticals drug candidates. Its BayMedica Commercial segment is engaged in the manufacturing technologies to produce and commercialize bulk rare cannabinoids for sale as ingredients in the health and wellness industry. Its pharmaceutical pipeline consists of three programs, with drug candidates targeting Alzheimer’s disease, dry age-related macular degeneration, and Epidermolysis Bullosa. Its INM-901 is a drug candidate being developed as a potential treatment for Alzheimer’s disease. Its INM-089 is cannabinoid analog being studied for its potential as a treatment for age-related macular degeneration. Its INM-755 is a cannabinol topical cream which has completed Phase 2 clinical trial studies for the treatment of epidermolysis bullosa.
Contact Information
- Headquarters
- 1445-885 West Georgia St.VANCOUVER, BC, Canada V6C 3E8
- Phone
- 604-669-7207
- Fax
- 778-945-6800
Executives
- Independent Chairman of the Board
- Andrew Hull
- President, Chief Executive Officer, Director
- Eric Adams
- Chief Financial Officer, Corporate Secretary
- N. Netta Jagpal
- Chief Operating Officer
- Michael Woudenberg
- Senior Vice President - Preclinical Research and Development
- Eric Hsu
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $3.2M |
|---|---|
Revenue (TTM) | $4.6M |
Shares Outstanding | 13.4M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.70 |
EPS | $-1.33 |
Book Value | $1.03 |
P/E Ratio | -0.2x |
Price/Sales (TTM) | 0.7 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -178.27% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
